Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – October 11, 2021
Idorsia Ltd (SIX: IDIA) today announced that MODIFY, the Phase 3 study to investigate the effect of lucerastat, as an oral substrate reduction therapy for the treatment of adult patients with Fabry disease, did not meet the primary endpoint.
Guy Braunstein, MD and Head of Global Clinical Developmentat Idorsia, commented:
“I’m very proud of everyone involved with MODIFY for delivering a very high-quality study, one of the largest in Fabry disease. Lucerastat was well tolerated and biochemically it did exactly what we were expecting; as previously seen, in this study we saw a substantial and consistent reduction of plasma Gb3, confirming the pharmacological activity of lucerastat. Despite this biological effect, no reduction in neuropathic pain was observed after six months of treatment, using the patient reported outcome tool.”
Guy Braunstein, added:
“In MODIFY, many parameters have been collected and data are still being analyzed. In addition, most patients chose to continue in the open-label extension study and in a few weeks, we will see more results that will inform our decision on the future of lucerastat.”
Jean-Paul Clozel, MD and Chief Executive Officer of Idorsia, commented:
“Taking into account the quality of the study, the volume of data we have collected, and some observations made in the six-month double-blind placebo-controlled treatment period, we need to wait for the results of the interim analysis of the open-label phase before making a decision. I expect to be in a position to share our future direction before the end of year.”
Notes to the editor
About the MODIFY study (NCT03425539)
MODIFY was a multicenter, double-blind, randomized, placebo‑controlled, parallel-group study to determine the efficacy and safety of lucerastat as an oral monotherapy in adult patients with Fabry disease. MODIFY determined the effect of study treatment on neuropathic pain during 6 months of treatment, measured with Idorsia’s validated Fabry disease pain instrument. 118 patients were randomized in a 2:1 ratio to either lucerastat or placebo. At the end of the double-blind period, 107 patients entered into an ongoing open label extension study (NCT03737214), which is investigating the long-term safety and tolerability of lucerastat oral therapy and to further evaluate its clinical efficacy on renal and cardiac function, in adult patients with Fabry disease over a period of up to a further 48 months.
About Fabry disease
Fabry disease is a rare, genetic, lysosomal storage disorder that results in reduced or absent α-galactosidase A (alpha-GalA) an enzyme that normally breaks down a fatty product known as globotriaosylceramide (Gb3) in the cells of the body. Over time, this results in an accumulation of Gb3 deposits throughout the body, leading to progressive pathophysiology in the nervous system, such as neuropathic pain (pain primarily in the hands and feet), the gastrointestinal system, and the cardiovascular system, as well as in organs, including the kidneys, skin, ears, eyes, and lung. Symptoms of Fabry disease affect a patient’s life expectancy and their quality of life. There is an unmet need for a well-tolerated, disease-modifying, oral treatment that addresses refractory symptoms and can be used regardless of GLA mutation or previous treatment.
Lucerastat in Fabry disease
Lucerastat, a small molecule glucosylceramide synthase inhibitor, is in development as a novel, substrate reduction therapy for Fabry disease. Preclinical studies showed that lucerastat is a soluble, bioavailable inhibitor of glucosylceramide synthase that reduces the accumulation of α-galactosidase A substrates in tissues affected by Fabry disease, including kidneys, liver, and dorsal root ganglia. In clinical pharmacology studies, lucerastat had reproducible pharmacokinetics, characterized by rapid absorption, quick elimination, and no evidence for saturation of absorption or elimination mechanisms. Across Phase 1 studies, lucerastat doses up to 4000 mg were well tolerated and the safety profile was not affected by concomitant treatments.
The safety, tolerability, pharmacodynamics, and pharmacokinetics of oral lucerastat were evaluated in an exploratory study in adult patients with Fabry disease. In this single-center, open-label, randomized study, 10 patients with Fabry disease were randomized to lucerastat for 12 weeks on top of ERT and 4 to ERT only. A rapid decrease in plasma Gb3, a marker of Fabry disease, and its precursors was observed, demonstrating that lucerastat 1000 mg b.i.d. inhibits glucosylceramide synthase and provides alpha-GalA substrate reduction with a fast onset in adult patients with Fabry disease receiving ERT.
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development, and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet – the ideal constellation to translate R&D efforts into business success.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 1000 highly qualified specialists dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Scientific Beta welcomes updated TCFD guidance and renews criticism of EU Climate Transition and Paris-Aligned Benchmark Regulation21.10.2021 10:21:50 CEST | Press release
Press Release - Boston, London, Nice, Paris, Singapore, Tokyo, October 21, 2021 Scientific Beta welcomes updated TCFD guidance and renews criticism of EU Climate Transition and Paris-Aligned Benchmark Regulation Index provider reiterates warnings against use of enterprise-value based carbon intensity and regards integration of implied temperature rise metrics into portfolio construction as premature On 15 October 2021, the Task Force on Climate-related Financial Disclosures (TCFD) updated its 2017 guidelines on implementing its recommendations that aim to promote more informed financial decisions in relation to the risks of climate change.1 The updated guidance: Promotes more granular or explicit disclosure of risks and opportunities identified by reporting organisations and how these impact their strategiesIntroduces significant revisions to the disclosures of metrics and targets to: Encourage the uptake of indicators that are relevant across industries and of related targetsRequire d
RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS21.10.2021 10:10:00 CEST | Press release
RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS Auction date2021-10-21Loan194Coupon1.00 %ISIN-codeSE0012142206Maturity2024-09-18 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln1,950 Volume bought, SEK mln500 Number of bids7 Number of accepted bids3 Average yield0.177 %Lowest accepted yield0.176 %Highest yield0.178 %% accepted at lowest yield 30.00 Auction date2021-10-21Loan1590Coupon1.00 %ISIN-codeSE0012676690Maturity2025-09-03 Tendered volume, SEK mln1,700 +/- 850 Volume offered, SEK mln4,200 Volume bought, SEK mln1,700 Number of bids6 Number of accepted bids2 Average yield0.378 %Lowest accepted yield0.378 %Highest yield0.381 %% accepted at lowest yield 85.29 Auction date2021-10-21Loan145Coupon1.00 %ISIN-codeSE0012481349Maturity2024-06-12 Tendered volume, SEK mln800 +/- 400 Volume offered, SEK mln2,400 Volume bought, SEK mln800 Number of bids5 Number of accepted bids1 Average yield0.115 %Lowest accepted yield0.115 %Highest yield0.115 %% accepted at lowest yield 100.
Kraftigere innsats kreves for kursendring mot klimamål21.10.2021 09:00:00 CEST | Pressemelding
(Oslo, 21. oktober 2021) -- Statkraft’s årlige Lavutslippsscenario maner til langt sterkere handling for å styre verden i retning av å nå 1,5-gradersmålet. Fornybar kraftproduksjon utgjør fortsatt kjernen i en slik strategi, men vi vil ikke lykkes uten utslippsfritt hydrogen, ifølge rapporten. - Verden er mobilisert til å samarbeide med ett mål for øyet – å redusere oppvarmingen av planeten vår. Dette er århundrets viktigste oppdrag, og vil definere vår generasjon. Med gradvis gjenåpning av samfunnet, stiger utslippene tilbake til nivåene fra før pandemien. Dette forsterker vårt syn om at en storstilt omlegging av energisystemet er helt nødvendig for å nærme oss en 1,5-gradersbane, sier konsernsjef Christian Rynning-Tønnessen i Statkraft. Hvert år utvikler Statkraft sitt Lavutslippsscenario, en omfattende analyse av utviklingen i verdens energimarkeder. Analysen danner grunnlaget for Statkrafts framtidige investeringer og for sjette året på rad deler vi nå våre nøkkelfunn: GRØNNE INVES
Greater action needed to shift global course to meet climate target21.10.2021 09:00:00 CEST | Press release
(Oslo, 21 October 2021) -- Statkraft’s annual Low Emissions Scenario urges greater action to shift global course to come close to a 1.5-degree climate target. Renewables remain at the core of this strategy, but we won’t succeed without clean hydrogen, according to the report. “The world has been called to arms, to work in unison to slow the warming of our planet. It’s the mission of a lifetime, one that will define our generation. With the world slowly re-opening, so too are emissions returning to pre-pandemic levels, reinforcing our belief that the only way towards a 1.5-degree path is through the energy transition,” says Statkraft Chief Executive Officer Christian Rynning-Tønnesen. Each year, Europe’s largest renewable energy generator develops its Low Emissions Scenario, analysing developments in the global energy markets. The analysis is used as a foundation for Statkraft’s future investments and for the sixth consecutive year, we now share our key findings: GREEN INVESTMENTS: Grow
Invitation to the press conference on Aspo's Interim report21.10.2021 09:00:00 CEST | Press release
Aspo Plc Press Release October 21, 2021 at 10 a.m. Invitation to the press conference on Aspo'sInterim report Aspo Plc will publish the Interim report for January-September 2021 on Wednesday, October 27, 2021, approximately at 9.30 a.m. Finnish time. A press conference for analysts, investors and media will be held at FLIK studio Eliel in Sanoma House (Töölönlahdenkatu 2, 00100 Helsinki, entrance inside the Sanoma House) on Wednesday, October 27, 2021 at 2 p.m. The Interim report will be presented by CEO Rolf Jansson, and the event will be held in Finnish. The presentation material will be available at www.aspo.com before the press conference. Registration beforehand to email@example.com, by Monday, October 25, 2021, at the latest. The press conference will be held in Finnish and it can also be followed by a live webcast at https://aspo.videosync.fi/2021-q3-results, or by calling +358 9 817 10310 (62598237#) 5 to 10 minutes before the beginning of the press conference. The recor
GeoJunxion (GOJXN.AS) is pleased to publish its 2020-‘21 Annual Accounts for the year ending 30 June 202121.10.2021 08:30:00 CEST | Press release
Capelle aan den IJssel, The Netherlands – 21 October 2021 – GeoJunxion (GOJXN.AS) publishes its 2020-’21 Annual Accounts for the 18-month accounting year ending 30 June 2021. We are delighted to present the GeoJunxion Annual Report for the accounting year 2020-21. It covers the 18-month period from 1 January 2020 to 30 June 2021. However, the comparative financials for 2019 relate to the 12-month period from 1 January to 31 December 2019. A copy of the document is attached to this press release and can be found on the company’s website www.geojunxnion.com, under the investor relations section. The 2020-21 accounting year was an eventful period during which the company underwent a complete metamorphosis. At the same time, we realized significant top line growth whilst keeping operating expenses flat on a like for like basis and significantly reduced the operating losses. All this during a time severely impacted by the COVID-19 pandemic. A summary of the key financials is provided in the
PGS ASA: Third Quarter 2021 Results21.10.2021 08:00:00 CEST | Press release
Further Contract Market Improvement Muted Late Sales Takeaways Q3 2021 Segment Revenues and Other Income of $131.7 million, compared to $116.1 million in Q3 2020Segment EBITDA of $55.6 million, compared to $88.4 million in Q3 2020Segment EBIT loss (excluding impairments and other charges) of $39.5 million, compared to profit of $0.5 million in Q3 2020Segment MultiClient pre-funding revenues of $35.3 million, with a corresponding pre-funding level of 101%, compared to $50.4 million and 89%, respectively, in Q3 2020Cash flow from operations of $114.5 million, compared to $65.9 million in Q3 2020 As Reported Revenues and Other Income according to IFRS of $141.7 million and an EBIT loss of $29.9 million, compared to $85.1 million and an EBIT loss of $4.3 million, respectively, in Q3 2020Awarded 3D acquisition contract by ExxonMobil for work offshore SurinameSecured pre-funding for Sarawak MultiClient campaignFirst significant carbon capture and storage (CCS) specific MultiClient sale “In t